Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors. Read more on ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow ...

Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive ...

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...